BR112017007363A2 - espiro-tiazolonas - Google Patents

espiro-tiazolonas

Info

Publication number
BR112017007363A2
BR112017007363A2 BR112017007363A BR112017007363A BR112017007363A2 BR 112017007363 A2 BR112017007363 A2 BR 112017007363A2 BR 112017007363 A BR112017007363 A BR 112017007363A BR 112017007363 A BR112017007363 A BR 112017007363A BR 112017007363 A2 BR112017007363 A2 BR 112017007363A2
Authority
BR
Brazil
Prior art keywords
thiazolones
spiro
present
desynchrosis
obsessive
Prior art date
Application number
BR112017007363A
Other languages
English (en)
Inventor
Fasching Bernhard
Dolente Cosimo
Schnider Patrick
Runtz-Schmitt Valerie
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112017007363A2 publication Critical patent/BR112017007363A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção fornece espiro-tiazolonas, que agem como moduladores do receptor de v1a e em particular como antagonistas do receptor de v1a, sua fabricação, composições farmacêuticas contendo-as e seu uso como medicamentos. os compostos presentes são úteis como terapêuticos agindo perifericamente e centralmente nas condições de secreção imprópria de vasopressina, ansiedade, transtornos depressivos, transtorno obsessivo-compulsivo, transtorno de espectro autista, esquizofrenia, comportamento agressivo e transtornos de sono de mudança de fase, em particular dessincronose.
BR112017007363A 2014-11-14 2015-11-11 espiro-tiazolonas BR112017007363A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14193294 2014-11-14
PCT/EP2015/076278 WO2016075181A1 (en) 2014-11-14 2015-11-11 Spiro-thiazolones

Publications (1)

Publication Number Publication Date
BR112017007363A2 true BR112017007363A2 (pt) 2017-12-19

Family

ID=51904773

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017007363A BR112017007363A2 (pt) 2014-11-14 2015-11-11 espiro-tiazolonas

Country Status (21)

Country Link
US (1) US10092551B2 (pt)
EP (1) EP3218381B1 (pt)
JP (1) JP6629855B2 (pt)
KR (1) KR20170084047A (pt)
CN (1) CN107001382B (pt)
AR (1) AR102633A1 (pt)
AU (1) AU2015345102A1 (pt)
BR (1) BR112017007363A2 (pt)
CA (1) CA2963188A1 (pt)
CL (1) CL2017001231A1 (pt)
CO (1) CO2017002963A2 (pt)
CR (1) CR20170195A (pt)
EA (1) EA201790919A1 (pt)
IL (1) IL250999A0 (pt)
MX (1) MX2017006294A (pt)
PE (1) PE20170671A1 (pt)
PH (1) PH12017500891A1 (pt)
SG (1) SG11201703604VA (pt)
TW (1) TW201625642A (pt)
WO (1) WO2016075181A1 (pt)
ZA (1) ZA201701914B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540633A (ja) * 2005-05-18 2008-11-20 ファイザー・リミテッド バソプレッシン拮抗薬としての１，２，４−トリアゾール誘導体
WO2008068185A1 (en) * 2006-12-07 2008-06-12 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives as via receptor antagonists
JP2010515700A (ja) * 2007-01-12 2010-05-13 エフ．ホフマン−ラ ロシュ アーゲー スピロピペリジングリシンアミド誘導体
AU2009315754B2 (en) * 2008-11-13 2013-08-15 F. Hoffmann-La Roche Ag Spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes
EP2956441A4 (en) * 2013-02-18 2016-11-02 Scripps Research Inst MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL

Also Published As

Publication number Publication date
PH12017500891A1 (en) 2017-11-06
PE20170671A1 (es) 2017-05-22
EA201790919A1 (ru) 2017-08-31
KR20170084047A (ko) 2017-07-19
JP2017533933A (ja) 2017-11-16
JP6629855B2 (ja) 2020-01-15
CO2017002963A2 (es) 2017-07-19
US10092551B2 (en) 2018-10-09
IL250999A0 (en) 2017-04-30
SG11201703604VA (en) 2017-06-29
CA2963188A1 (en) 2016-05-19
EP3218381B1 (en) 2019-01-23
MX2017006294A (es) 2017-08-21
CR20170195A (es) 2017-05-31
EP3218381A1 (en) 2017-09-20
CN107001382B (zh) 2019-10-25
CN107001382A (zh) 2017-08-01
TW201625642A (zh) 2016-07-16
AU2015345102A1 (en) 2017-03-30
CL2017001231A1 (es) 2018-01-12
US20170246153A1 (en) 2017-08-31
ZA201701914B (en) 2018-12-19
AR102633A1 (es) 2017-03-15
WO2016075181A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
PH12016500094A1 (en) Autotaxin inhibitors
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
MX2016012451A (es) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina.
PH12017501280B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
MX2017005484A (es) Compuestos antagonistas del receptor de dopamina d3.
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
UY35708A (es) Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico
ECSP14032516A (es) N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas como antagonistas del receptor de andrógenos, su producción y usos como productos medicinales
CR20160215A (es) Espiro-oxazolonas
CR20160373A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
MX2016009501A (es) Espiro-oxazolonas.
BR112017007363A2 (pt) espiro-tiazolonas
GT201600190A (es) Compuestos químicos
MX2017008497A (es) Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética.
TH148806B (th) สูตรผสมทางเภสัชกรรมที่มีความคงตัวดีขึ้น

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]